Cardio Diagnostics Holdings, Inc. (CDIO)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Artificial Intelligence-driven DNA Biomarker Testing Technology	17.07K
Artificial Intelligence-driven DNA Biomarker Testing Technology Growth	1696.32%

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	17.07K
United States Growth	1696.32%